Immpact Bio
ImmPACT Bio is developing cutting-edge potent and selective chimeric antigen receptor (CAR) T-cell technologies to address key biological challenges in treating cancer. In 2021 ImmPACT Bio merged with Kalthera Therapeutics. The company's latest investment round exceeded $100M.
Website
The future of CAR T-Cell therapies
Click on the image to scroll the full page
Website
Pitch Deck
We needed a cutting-edge website. One that positions CBI as the leading life sciences holding company in Israel. CadenSee created a clean and user-friendly website that is extremely easy to manage. It was completely turn-key. saving us a lot of time – from site structure to content writing to design. They used the latest web technologies so that the site is fast to load on any device. Their services are highly recommended.
Ofer Goldberg
Vice President
Get in Touch and let's talk Medical
You can contact us in multiple ways: By email, filling the form on the right, and LinkedIn. Let's start!